Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (7)
Language
- English (7)
Keywords
- radiotherapy (3)
- chemotherapy (2)
- surgery (2)
- AT/RT (1)
- EU-RHAB registry (1)
- EU‐RHAB Registry (1)
- RTPS1 (1)
- RTPS2 (1)
- Rhabdoid 2007 (1)
- adverse events (1)
- atypical teratoid rhabdoid tumors (1)
- brain cancer (1)
- brain tumor (1)
- childhood cancer (1)
- children (1)
- extracranial malignant rhabdoid tumor (1)
- focal radiotherapy (1)
- germline mutation (1)
- imaging changes (1)
- individual case review (1)
- intraventricular therapy (1)
- medulloblastoma (1)
- pediatric (1)
- pediatric adrenocortical cancer (1)
- pediatric adrenocortical carcinoma (1)
- pediatric adrenocortical tumor (1)
- pediatric brain tumor (1)
- pediatric low‐grade glioma (1)
- progression (1)
- proton beam therapy (1)
- quality assurance (1)
- re-irradiation (1)
- recurrent (1)
- refractory (1)
- therapy (1)
- treatment (1)
Atypical teratoid rhabdoid tumors (AT/RT) are characterized by mutations and subsequent inactivation of SMARCB1 (INI1, hSNF5), a predilection for very young children and an unfavorable outcome. The European Registry for rhabdoid tumors (EU‐RHAB) was established to generate a common European database and to establish a standardized treatment regimen as the basis for phase I/II trials. Thus, genetic analyses, neuropathologic and radiologic diagnoses, and a consensus treatment regimen were prospectively evaluated. From 2005 to 2009, 31 patients with AT/RT from four countries were recruited into the registry study Rhabdoid 2007 and treated with systemic and intraventricular chemotherapy. Eight patients received high‐dose chemotherapy, 23 radiotherapy, and 17 maintenance therapy. Reference evaluations were performed in 64% (genetic analyses, FISH, MLPA, sequencing) up to 97% (neuropathology, INI1 stain). Germ‐line mutations (GLM) were detected in 6/21 patients. Prolonged overall survival was associated with age above 3 years, radiotherapy and achievement of a complete remission. 6‐year overall and event‐free survival rates were 46% (±0.10) and 45% (±0.09), respectively. Serious adverse events and one treatment‐related death due to insufficiency of a ventriculo peritoneal shunt (VP‐shunt) and consecutive herniation were noted. Acquisition of standardized data including reference diagnosis and a standard treatment schedule improved data quality along with a survival benefit. Treatment was feasible with significant but manageable toxicity. Although our analysis is biased due to heterogeneous adherence to therapy, EU‐RHAB provides the best available basis for phase I/II clinical trials.